Fraser, Christopher,Kishimoto, Takashi Kei,Maldonado, Roberto A.
申请号：
AU2019232928
公开号：
AU2019232928A1
申请日:
2019.09.20
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
#$%^&*AU2019232928A120191010.pdf#####ABSTRACT Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class IIrestricted epitopes that can generate tolerogenic immune responses (e.g., antigen- specific T effector cell deletion). See Fig. 5.WO 2012/149393 PCT/US2012/035555 3/3 5- 1.50 20 0 0- 0.0--UlA = lA ~ ~>； ~ ~ >； D~0 LA D 0 Ln z z Fig. 4 5- 2.5u U 4-~ 2.0co T 0 3- C) 1.50) 0) 1.0>； . 0.5E Q ~~0.0111 1 0i Ul 0 LA = C CL0 LA - LA N NN z z Fig. 5
